Hims & Hers stock slipped as investors were left unimpressed with its new weight-loss drug options
Hims & Hers (HIMS) stock slid Wednesday, a day after the company announced new weight-loss drug offerings — an update
Hims & Hers (HIMS) stock slid Wednesday, a day after the company announced new weight-loss drug offerings — an update
After revolutionizing the weight-loss drug market, Novo Nordisk (NVO) and Eli Lilly (LLY) are setting their sights on heart health.Read
Johnson & Johnson (JNJ) is joining Eli Lilly (LLY) in attempting to court favor with President Donald Trump by announcing
Several weight loss drug stocks are sliding today as pharmaceutical companies battle for dominance in the booming GLP-1 market —
A group that represents pharmacies that have been producing off-brand versions of GLP-1 weight-loss drugs just filed another lawsuit against
Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound doubled in the fourth quarter year over year, despite missing the
Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound surged in the fourth quarter, despite missing the company’s initial sales
The cost of prescription drugs is set to climb in 2025 and beyond, according to TD Cowen’s 30th Annual Drug
Belgium is banning the sale of disposable electronic cigarettes starting Jan. 1, becoming the first European Union country to do
Healthcare professionals in the U.S. have noticed a significant increase in vaccine hesitancy among their patients, according to a survey
No posts found.